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Summary
Common variable immunodeﬁciency (CVID) is the most
frequent clinically manifested primary immunodeﬁciency.
According to clinical and laboratory ﬁndings, CVID is a
heterogeneous group of diseases. Recently, the defects of
molecules regulating activation and terminal differentia-
tion of B lymphocytes have been described in some patients
with CVID. In this study, we show the overview of
deﬁciencies of inducible costimulator, transmembrane
activator and calcium-modulator and cytophilin ligand
interactor, CD19 molecules, their genetic basis, pathogenesis
and clinical manifestations.
Introduction
Common variable immunodeﬁciency (CVID) is a hetero-
geneous group of diseases characterized by hypogamma-
globulinemia and repeated, predominantly, bacterial
infections. Most of the patients have the normal number
of peripheral T and B lymphocytes. B lymphocytes, how-
ever, show defects of differentiation and proliferation after
antigen stimulation. The number of plasma and memory
cells is reduced. As a result of this, the values of serum IgG
and IgA are reduced and also irregularly the values of IgM
(Di Renzo et al., 2004). The antibody response to protein
and polysaccharide antigens is insufﬁcient or completely
missing in some cases. The attempts to classify CVID
based on in vitro immunoglobulin (Ig) production and B
lymphocyte subsets have conﬁrmed marked heterogeneity
of this antibody defects (Weiler & Bankers-Fulbright,
2005). Differentiation of precursor cells into mature B
lymphocytes and then into plasma cells is a process
regulated by products of a number of genes. Mutation of
genes for inducible costimulator (ICOS), the ﬁrst single
gene defect, has been described in patients with CVID
(Grimbacher et al., 2003). Subsequently, the mutations of
genes encoding transmembrane activator and calcium-
modulator and cytophilin ligand interactor (TACI) and
CD19 have been found.
ICOS deﬁciency
The ICOS molecule was described by Hutloff et al. (1999).
It ranks in the family of costimulation molecules similarly
as CD28 and CTLA-4 (CD152) molecules. It is encoded
by three genes that are mapped to chromosome 2q33. A
great number of single nucleotide variants that participate
in the ICOS polymorphisms have been reported. The
comparison of the frequency of single nucleotide poly-
morphisms between patients and healthy controls showed
no signiﬁcant differences (Haaning Andersen et al., 2003;
Guzman et al., 2005; Ohm-Laursen et al., 2005). The
ICOS and CD28 molecules share up to 20% amino acid
homology and both are type I transmembrane receptors.
ICOS occurs as a homodimer, with an extracellular (Ig) V
like domain. Unlike the CD28 molecule, which is expressed
constitutively, the ICOS molecule is expressed only on
activated T lymphocytes. The ICOS expression is up-
regulated within hours after TcR engagement. Its mem-
brane expression persists on recently activated as well as
on memory Th1 and Th2 CD4
+ lymphocytes (van Berkel
& Oosterwegel, 2006; Warnatz et al., 2006). The ICOS
expression appears to be higher on Th2 cells compared to
Th1 CD4
+ T cells (Coyle et al., 2000). The Th2-mediated
response is more dependent on the ICOS function than
Th1 response (Löhning et al., 2003; Grunig et al., 2005).
The density of ICOS membrane expression correlates
with cytokine production. In case of ICOS gene muta-
tion, especially the synthesis of cytokine associated with
high-level ICOS expression (IL-10, IL-2, IL-4, IL-5, IL-13)
is disturbed. Within the course of viral or bacterial infec-
tions in knock-out ICOS
−/
− mice, large secondary germ
centres fail to develop, and speciﬁc antibody response is
missing. Both the reduced proliferation Th2 activity and
the failure of T and B lymphocyte co-operation participate
in the developed antibody defect (van Berkel & Ooster-
wegel, 2006; Warnatz et al., 2006) (Figure 1).
Triggering  of TcR with appropriate costimulation leads
to gene transcription in the nucleus. The intracellular tail
of the ICOS molecule contains two tyrosine residues, one
of which lies within the YTyr180MEM motive, which is
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associated with adapter molecule grow factor receptor-
bound protein-2 (Grb-2). One amino acid replacement at
the position in this motive includes explaining of the lack
of capability to recruit Grb-2. This molecule plays a
key role during the initiation of IL-2 synthesis (Harada
et al., 2003). This ﬁnding explains why activating signals
coming through defective ICOS molecules do not lead to
synthesis of IL-2 (Itoh et al., 2002).
Activated T lymphocytes amplify the ICOS-L expression
on B lymphocytes through IL-4, IL-5, IL-6, granulocyte
macrophage colony-stimulating factor (GM-CSF), IFNγ
and tumour necrosis factor (TNF)α cytokines (Bayry et al.,
2005). ICOS-L expression on B lymphocytes is also up-
regulated through CD40 and CD154 ligands or bacterial
superantigens (Salzer et al., 2004; Janke et al., 2006). The
ICOS: ICOS-L interaction is necessary for IL-10, IL-17
synthesis (Chtanova et al., 2004; Warnatz et al., 2006).
The ICOS-L molecule is encoded by one gene, which is
found on the long arm of chromosome 21 (mapped
21q22.3). It exists in two splice variants that differ in
cytoplasmatic tail. The B7H2 variant is encoded by exon
1–7 and appears on both lymphoid and non-lymphoid
cells. The hGL-50 variant is encoded by exon 1–6 and 8,
and is found only on lymphoid cells (Ohm-Laursen et al.,
2005; Warnatz et al., 2006). The ICOS-L is the receptor
only for ICOS. Interaction of ICOS — ICOS-L molecules
is important for differentiation of naive B lymphocytes
into memory and plasma cells. ICOS-L ligand shares up to
20% homology with CD80 and CD86 molecules (recep-
tors for CD28 and CTLA-4 molecules) (Salzer et al.,
2004; van Berkel & Oosterwegel, 2006).
The homozygous deletion of ICOS causes an antibody
deﬁciency syndrome in affected individuals. The clinical
phenotype includes recurrent and serious bacterial
infections, autoimmune phenomena, splenomegaly,
lymphadenopathy and malignancy. Patients with CVID,
based on ICOS defect, have mild B lymphopaenia and
signiﬁcantly reduced number of memory CD19
+/CD27
+ B
lymphocytes (Warnatz et al., 2002; Piqueras et al., 2003).
This laboratory ﬁnding is not, however, characteristic
for ICOS mutations because up to 75% of patients with




– B lymphocytes (Schejbel et al., 2005).
However, patients with ICOS deﬁciency belong to CVID
type I group (Freigburg classiﬁcation) (Warnatz et al., 2002;
Carsetti et al., 2005). ICOS deﬁciency, based on one point
mutation, was the ﬁrst example of an autosomal recessive
disorder that occurs only in a small amount of patients
with CVID (approximately 2%) (Warnatz et al., 2006).
TACI deﬁciency
In order to ensure physiological antibody response after
antigen stimulation, other activation signals mediated
by both intracellular interactions and soluble factors are
important (Kroczek et al., 2004). Class switch recombina-
tion (CSR) of Ig synthesis requires four signals. The ﬁrst
one is mediated by IL-3, IL-4, IL-5, IL-6, IL-13 cytokines,
which participate in CH genes transcription regulation. In
case of a T-cell–dependent antibody response, the interac-
tion of CD40L (CD154) molecule expressed on activated
T lymphocytes with CD40 molecule on B lymphocytes
is necessary (McHeyzer-Williams, 2003). Costimulatory
ICOS — ICOS-L interaction constitutes the third necessary
stimulus for sufﬁcient antibody production. The fourth
signal is mediated by other interactions of molecules, which
belong to the superfamily of TNF molecules (B-cell–acting
factor of the TNF family (BAFF), A proliferation-inducing
ligand (APRIL)), and their receptors (B-cell maturation
antigen (BCMA), BAFF receptor (BAFF-R), TACI).
The BAFF and APRIL are among these molecules
(Castigli et al., 2005a). BAFF is present predominantly
on monocytes/macrophages, dendric cells and T lympho-
cytes (Mackay & Ambrose, 2003). On the contrary, it is
not expressed on B lymphocytes although this molecule
has been detected on B-cell–derived chronic lymphatic
leukaemia (Novak et al., 2002). The APRIL molecule
is expressed on a large variety of cells, monocytes/
Figure 1. The cascade of co-stimulation signals 
between T and B lymphocytes. The expression 
of CD154 (CD40L) and ICOS is up-regulated 
through constitutively surface expressed 
CD28 molecule and its CD80/CD86 ligands. 
CD40-CD154 ligand ampliﬁes the expression 
of CD80/CD86 and ICOS-L. By this another 
support of co-stimulation ligands between T and 
B lymphocytes occurs through ICOS-ICOS-L 
which up-regulates CD154 expression.Genetic defects in CVID 227
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macrophages, dendritic cells and activated T lymphocytes.
BAFF and APRIL molecules rank as type II membrane
receptors. They exist as membrane molecules and are in
soluble form. BAFF and APRIL molecules create both
homotrimers and heteromers capable of stimulating B
lymphocyte differentiation (Wu et al., 2000; Locksley
et al., 2001). It has been proved that APRIL and BAFF
molecules interfere with CSR of T-independent antibody
response (Litinskiy et al., 2002; Martin & Vishva, 2005).
Both APRIL and BAFF molecules bind two type III
membrane receptors, BCMA, TACI (Schneider et al.,
1999). Both receptors belong to a superfamily of TNF
receptors. BCMA is expressed exclusively on B lympho-
cytes while TACI is expressed both on B lymphocytes and
activated T lymphocytes. The third receptor belonging to
the TNF-R family is the BAFF-R, which is the unique
receptor for BAFF (Bodmer et al., 2002; Losi et al., 2005).
This membrane molecule is predominantly expressed on
B lymphocytes and only on part of activated T lympho-
cytes (Schneider & Tschopp, 2003; Martin & Vishva,
2005). Interactions of APRIL and BAFF, expressed on
monocytes and macrophages, with their receptors on B
lymphocytes are evidence of the signiﬁcance of natural
immunity for the correct antibody response (McHeyzer-
Williams, 2003; de Durana et al., 2006). The absence of
any of the previously mentioned signals is the cause
for defect of terminal differentiation of a mature B
lymphocyte into plasmatic and memory cells, which
are manifested by antibody immunodeﬁciency (Salzer &
Grimbacher, 2005) (Figure 2).
Receptor TACI molecules are encoded by the
TNFRSF13b gene, which is situated at the short arm of
chromosome 17 (17p11.2). The described mutations affect
TACI molecule in its extracellular (C104R, S144X),
transmembrane (A181E) and intracellular parts (S194X,
R202H, Ins204) (Castigli et al., 2005b). Both homozy-
gous and heterozygous TNFRSF13b mutations are
associated with antibody deﬁciencies (Salzer et al., 2005).
This suggests that TACI deﬁciency may manifest in auto-
somal dominant as well as in recessive traits in familial
and in sporadic CVID. In the case of heterozygous muta-
tions, the clear evidence that they are the cause of humoral
deﬁciencies has not been shown. It is not possible to
exclude that heterogeneous mutations may be the only
modifying factor that leads to the manifestation of other
defects. The TACI mutations show a range of clinical
symptoms from no infection to very severe infections,
suggesting that other genetic and environmental factors
contribute to the variable disease spectrum. In addition,
TACI deﬁciency may also represent a common genetic
defect for CVID and selective IgA deﬁciency (sIgAD),
which has been long proposed to be based on the
clinical observations in CVID/sIgAD families (Salzer &
Grimbacher, 2006).
The numbers of B cells in homozygous TACI deﬁciency
are normal or tend to be slightly reduced. Patients with
homozygous mutations in TACI showed selective impair-
ment of APRIL and BAFF-induced B-cell proliferation




B lymphocytes and suffer from severe infections caused by
encapsulated microbes. The vaccination with non-
conjugated vaccines is not effective. In the case of
homozygous TACI mutations, polysaccharide antigens
are followed by a disturbance in the proliferation of B
lymphocytes (Castigli et al., 2005b).
Unlike knock-out TACI
–/
– mice, in which spontaneous
development of lymphomas occur, only one case of
malignant lymphoma has been described in patients with
TACI mutation (Seshasayee et al., 2003). The increased
incidence of lupus-like disease seen in TACI
–/
– mice was
not observed in CVID patients with the same defect. In
case of patients with CVID, the incidence of autoimmune
manifestations in patients with and without TACI defect
is the same. The incidence of TNFRSF13b mutations is
estimated to be in 5–10% of patients with CVID (Salzer
& Grimbacher, 2006).
Figure 2. TNF receptor family members, 
BAFF-R, BCMA and TACI, and their ligands 
BAFF and APRIL check terminal differentiation 
of B lymphocytes and/or CSR of Ig synthesis. 
TNF receptors and their ligands regulate both 
the survival and the apoptosis during immune 
system development and immune responses. 
Dashed lines show the interactions with limited 
functions.228 O. Kopecky & x. Lukeßová
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CD19 molecule deﬁciency
The CD19 molecule is detectable in the cytoplasm of B
lymphocyte precursors, and from the stage of immature
B lymphocytes it is imbedded in the cell membrane. It
participates in feedback regulation of signals which come
through BcR. On the other hand, it facilitates the recogni-
tion of antigen-antibody complexes that link to BcR and
the CD21 molecule. Together with the CD21 molecule, it
ensures another communication between natural immunity
and B lymphocytes. van Zelm described the homozygous
mutation in the CD19 gene in four members of a family
with antibody deﬁciency that complies with classiﬁcation
criteria for CVID. The encoding gene is situated on the
short arm of chromosome 16 (mapped 16p11.2) (van
Zelm et al., 2006). The defect is autosomally recessive. Its
real frequency is unknown in patients with CVID because
the ﬁndings discovered up to now are rare. The numbers
of peripheral B lymphocytes are normal or only slightly
reduced in affected individuals. CD19 expression on B
lymphocytes is missing and as a result of this, the expres-
sion of CD21 surface molecules is reduced. Calcium
inﬂux into cells is disturbed (McHeyzer-Williams, 2003).
The hypersomatic mutation process proceeds in a normal
way; however, CD27
+ B lymphocytes are missing. Post-
activation antibody response to rabies vaccine is insufﬁ-
cient. In diagnosed individuals, the defect was manifested
by repeated bacterial infections. Autoimmune and lym-
phoproliferative symptoms were not observed (van Zelm
et al., 2006).
Conclusion
In 1953 Janeway described a case of a 39-year-old woman
with hypogammaglobulinaemia, which is considered the
ﬁrst mention of CVID. More than 50 years have passed
during which separate pathological units, as for example
hyper IgM syndrome linked and unlinked to X-chromosome
and autosomal recessive agammaglobulinaemia, have been
excluded. In the last 3 years, mutations of genes encoding
ICOS, TACI and CD19 have been described. These
defects are found in less than 15% of the patients and for
this reason the etiology of most of the patients with CVID
remains unknown. The described mutations and ﬁndings
of other expected gene defects will probably cause
disintegration of this heterogeneous antibody deﬁciency
syndrome.
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